Profitability ratios measure the company ability to generate profitable sales from its resources (assets).
Paying user area
Try for free
Vertex Pharmaceuticals Inc. pages available for free this week:
- Income Statement
- Balance Sheet: Assets
- Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
- Analysis of Liquidity Ratios
- Analysis of Short-term (Operating) Activity Ratios
- Enterprise Value to EBITDA (EV/EBITDA)
- Price to FCFE (P/FCFE)
- Operating Profit Margin since 2005
- Return on Assets (ROA) since 2005
- Total Asset Turnover since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Vertex Pharmaceuticals Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Profitability Ratios (Summary)
Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
The data presents financial performance metrics over multiple quarters, highlighting trends in profitability and returns for the analyzed entity.
- Gross Profit Margin
- The gross profit margin remains consistently high across the periods from March 2021 to June 2025, maintaining a range approximately between 86% to 88%. Initially stable around 88% through 2021 to early 2023, a gradual decline begins in 2023, descending to approximately 86% by mid-2025. Despite this decrease, the margin indicates strong cost control relative to revenue throughout the timeframe.
- Operating Profit Margin
- This margin exhibits more volatility. After steady performance near 46%-48% in 2021 and into early 2022, the margin increases to nearly 49% by late 2022. Thereafter, it shows a declining trend throughout 2023, falling to approximately 38%-41%. In the year 2024, operating profitability sharply deteriorates, turning negative in most quarters, reaching as low as -6.69% at year-end 2024. Interestingly, a strong recovery is observed in the first quarter of 2025, with the margin rebounding to 34.36%. This pattern suggests fluctuating operating expenses or changes in revenue recognition affecting operational efficiency.
- Net Profit Margin
- Similar to operating margin trends, the net profit margin starts high, around 43%-44% in early 2021. It declines steadily through 2022 and 2023, settling near 35%. The margin further dips into negative territory during 2024, reaching approximately -8.91% before recovering sharply to 31.86% in the first quarter of 2025. This illustrates a period of significant profitability challenges during 2024, followed by a rapid improvement.
- Return on Equity (ROE)
- ROE follows a declining trend overall, starting at above 30% in early 2021 and reducing gradually through 2023 to about 20%-22%. The year 2024 again reflects a sharp downturn, with ROE turning negative in most quarters, reaching a low near -5.99%. A strong recovery is seen in the first quarter of 2025, climbing back to 21.18%. This indicates variability in shareholder returns, correlating with fluctuation in earnings performance and possibly changes in equity or financial leverage.
- Return on Assets (ROA)
- ROA exhibits a consistent downward trend from over 23% in early 2021 to around 16%-17% during 2023. The year 2024 observes a decline into negative values, bottoming near -4.32%, similar to other profitability indicators, before recovering to 15.13% by March 2025. This reflects asset utilization efficiency challenges aligned with the net and operating profit trends.
Overall, the data reveals a pattern of robust profitability and return metrics sustained through 2021 and 2022, followed by a marked deterioration across all key margins and return ratios during 2024. This downturn is substantial, with multiple metrics turning negative, indicating a period of operational and financial stress. The first quarter of 2025 shows signs of recovery, suggesting a potential rebound in profitability and return on investments. The gradual decline in gross profit margin over the longer term may reflect cost pressures or pricing changes that could warrant further investigation.
Return on Sales
Return on Investment
Gross Profit Margin
Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | |||||||||||||||||||||||||||||
Gross profit | |||||||||||||||||||||||||||||
Revenues | |||||||||||||||||||||||||||||
Profitability Ratio | |||||||||||||||||||||||||||||
Gross profit margin1 | |||||||||||||||||||||||||||||
Benchmarks | |||||||||||||||||||||||||||||
Gross Profit Margin, Competitors2 | |||||||||||||||||||||||||||||
AbbVie Inc. | |||||||||||||||||||||||||||||
Amgen Inc. | |||||||||||||||||||||||||||||
Bristol-Myers Squibb Co. | |||||||||||||||||||||||||||||
Danaher Corp. | |||||||||||||||||||||||||||||
Eli Lilly & Co. | |||||||||||||||||||||||||||||
Gilead Sciences Inc. | |||||||||||||||||||||||||||||
Johnson & Johnson | |||||||||||||||||||||||||||||
Merck & Co. Inc. | |||||||||||||||||||||||||||||
Pfizer Inc. | |||||||||||||||||||||||||||||
Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. |
Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q2 2025 Calculation
Gross profit margin = 100
× (Gross profitQ2 2025
+ Gross profitQ1 2025
+ Gross profitQ4 2024
+ Gross profitQ3 2024)
÷ (RevenuesQ2 2025
+ RevenuesQ1 2025
+ RevenuesQ4 2024
+ RevenuesQ3 2024)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
- Gross Profit Trend
- The gross profit of the company exhibited a consistent upward trend over the analyzed periods. Beginning at approximately 1.35 billion US dollars in the first quarter of 2020, gross profit showed gradual increases with periodic fluctuations, reaching around 2.56 billion US dollars by mid-2025. Notably, there were slight decreases or plateaus towards the end of 2022 and late 2023, but these were followed by renewed growth in subsequent quarters, indicating overall positive performance in gross profitability.
- Revenues Trend
- Revenues followed a similar positive trajectory as gross profit, starting at approximately 1.52 billion US dollars in early 2020 and increasing steadily to nearly 3 billion US dollars by mid-2025. The increments were consistent over time, with minor fluctuations observed that align with those in gross profit. The revenue increases reflect a healthy expansion in business operations and sales volume over the observed period.
- Gross Profit Margin Analysis
- The gross profit margin data available from March 2021 onward indicate a relatively stable margin close to 87-88%. The margin peaked just above 88% in early 2021, followed by a gradual declining pattern to about 86% by mid-2025. Although the margin exhibits a slow downtrend, it remains high overall, suggesting efficient cost management relative to revenues despite the slight erosion over time.
- Interrelationships and Insights
- The parallel increase in revenues and gross profit suggests that growth in sales has been effectively converted into profit, maintaining operational profitability. However, the modest decline in gross profit margin hints at increasing costs or changes in product mix slightly impacting profitability per unit of revenue. The consistently high margins indicate that the company has sustained strong pricing power or cost control measures despite competitive or market pressures.
Operating Profit Margin
Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | |||||||||||||||||||||||||||||
Income (loss) from operations | |||||||||||||||||||||||||||||
Revenues | |||||||||||||||||||||||||||||
Profitability Ratio | |||||||||||||||||||||||||||||
Operating profit margin1 | |||||||||||||||||||||||||||||
Benchmarks | |||||||||||||||||||||||||||||
Operating Profit Margin, Competitors2 | |||||||||||||||||||||||||||||
AbbVie Inc. | |||||||||||||||||||||||||||||
Amgen Inc. | |||||||||||||||||||||||||||||
Bristol-Myers Squibb Co. | |||||||||||||||||||||||||||||
Danaher Corp. | |||||||||||||||||||||||||||||
Eli Lilly & Co. | |||||||||||||||||||||||||||||
Gilead Sciences Inc. | |||||||||||||||||||||||||||||
Johnson & Johnson | |||||||||||||||||||||||||||||
Merck & Co. Inc. | |||||||||||||||||||||||||||||
Pfizer Inc. | |||||||||||||||||||||||||||||
Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. |
Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q2 2025 Calculation
Operating profit margin = 100
× (Income (loss) from operationsQ2 2025
+ Income (loss) from operationsQ1 2025
+ Income (loss) from operationsQ4 2024
+ Income (loss) from operationsQ3 2024)
÷ (RevenuesQ2 2025
+ RevenuesQ1 2025
+ RevenuesQ4 2024
+ RevenuesQ3 2024)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
The financial data reveals several notable trends and variations in key performance indicators over the examined periods.
- Income (loss) from operations
-
Income from operations fluctuated considerably across quarters, with periods of significant growth followed by notable declines. Early in the timeline, quarterly income maintained a generally strong level ranging from approximately 672 million to over 1 billion US dollars. However, there were sharp downturns notably in June 2021 and June 2024, where the income from operations registered negative values of roughly 38 million and 3.5 billion US dollars, respectively, indicating operational challenges or extraordinary expenses in those periods. Between these declines, the income showed recovery and stabilization, often exceeding 1 billion US dollars. The overall pattern suggests episodic volatility rather than steady growth or decline.
- Revenues
-
Revenues exhibited a consistent upward trend throughout the periods. Starting at approximately 1.5 billion US dollars in early 2020, revenues increased steadily each quarter, reaching peaks above 2.9 billion US dollars by early 2025. Despite minor fluctuations and plateau phases, the general trajectory is positive with sustained revenue growth, reflecting possibly expanding market penetration or increased sales volume.
- Operating profit margin
-
The operating profit margin showed variability with a generally strong performance across many quarters. From the first reported margin of 46.03% in March 2021, the figures mostly ranged between about 33.93% and 48.85% through to December 2023, indicating strong profitability relative to revenues during these periods. However, there are sharp declines in mid to late 2024, with margins turning negative, hitting lows as severe as -6.69% in December 2024, signifying periods of operational loss despite revenue growth. By March 2025, the margin rebounded to 34.36%, suggesting a recovery in operational efficiency or cost management.
In summary, the data illustrates a company with robust revenue growth but facing significant volatility in operational income and profitability margins during certain quarters. The negative margins and losses in specific intervals highlight potential periods of operational difficulties or strategic investments adversely impacting short-term profitability. Nevertheless, the recovery in subsequent quarters points to an ability to regain operational control and sustain profitable growth over time.
Net Profit Margin
Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | |||||||||||||||||||||||||||||
Net income (loss) | |||||||||||||||||||||||||||||
Revenues | |||||||||||||||||||||||||||||
Profitability Ratio | |||||||||||||||||||||||||||||
Net profit margin1 | |||||||||||||||||||||||||||||
Benchmarks | |||||||||||||||||||||||||||||
Net Profit Margin, Competitors2 | |||||||||||||||||||||||||||||
AbbVie Inc. | |||||||||||||||||||||||||||||
Amgen Inc. | |||||||||||||||||||||||||||||
Bristol-Myers Squibb Co. | |||||||||||||||||||||||||||||
Danaher Corp. | |||||||||||||||||||||||||||||
Eli Lilly & Co. | |||||||||||||||||||||||||||||
Gilead Sciences Inc. | |||||||||||||||||||||||||||||
Johnson & Johnson | |||||||||||||||||||||||||||||
Merck & Co. Inc. | |||||||||||||||||||||||||||||
Pfizer Inc. | |||||||||||||||||||||||||||||
Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. |
Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q2 2025 Calculation
Net profit margin = 100
× (Net income (loss)Q2 2025
+ Net income (loss)Q1 2025
+ Net income (loss)Q4 2024
+ Net income (loss)Q3 2024)
÷ (RevenuesQ2 2025
+ RevenuesQ1 2025
+ RevenuesQ4 2024
+ RevenuesQ3 2024)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
- Revenue Trends
- Revenues demonstrated a consistent upward trend from March 2020 through June 2025, with minor fluctuations. Starting at approximately 1.52 billion USD in March 2020, revenues rose steadily, reaching peaks above 2.9 billion USD by the end of the period. This reflects sustained growth and expansion of the company’s sales over multiple quarters. A slight decline was observed in some quarters, but overall the trajectory is positive.
- Net Income Performance
- Net income showed considerable volatility throughout the observed quarters. Initial quarters reflect strong profitability with net income figures predominantly above 600 million USD through March 2021. Substantial fluctuations appeared subsequently, with some quarters exceeding 1 billion USD in net income. A notable exception occurs in mid-2024, where one quarter showed a significant loss of approximately 3.59 billion USD, followed by recovery in subsequent quarters back to positive territory. This indicates occasional substantial adverse impacts, potentially from extraordinary or non-recurring events.
- Net Profit Margin Analysis
- Net profit margins remained generally robust and consistent in most periods, often ranging between 30% and 40%. This implies a strong ability to convert revenues into profitability. However, during the middle of the timeline, particularly around mid-2024, margins turned negative, indicating losses. The margin recovered sharply after this downturn, ending the period with a high positive margin exceeding 30%. This pattern underscores a temporary disruption in profitability that was effectively managed and reversed.
- Summary of Financial Health Trends
- The financial data reveals sustained revenue growth supported by generally healthy and stable profit margins. The erratic net income results, particularly the extreme loss in mid-2024, suggest episodic challenges but do not detract from the overarching growth and profitability trend. The company appears resilient with the capacity to return to strong profit levels promptly after setbacks. Continuous monitoring of such volatility is recommended to understand its causes and mitigate future risks.
Return on Equity (ROE)
Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | |||||||||||||||||||||||||||||
Net income (loss) | |||||||||||||||||||||||||||||
Shareholders’ equity | |||||||||||||||||||||||||||||
Profitability Ratio | |||||||||||||||||||||||||||||
ROE1 | |||||||||||||||||||||||||||||
Benchmarks | |||||||||||||||||||||||||||||
ROE, Competitors2 | |||||||||||||||||||||||||||||
AbbVie Inc. | |||||||||||||||||||||||||||||
Amgen Inc. | |||||||||||||||||||||||||||||
Bristol-Myers Squibb Co. | |||||||||||||||||||||||||||||
Danaher Corp. | |||||||||||||||||||||||||||||
Eli Lilly & Co. | |||||||||||||||||||||||||||||
Gilead Sciences Inc. | |||||||||||||||||||||||||||||
Johnson & Johnson | |||||||||||||||||||||||||||||
Merck & Co. Inc. | |||||||||||||||||||||||||||||
Pfizer Inc. | |||||||||||||||||||||||||||||
Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. |
Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q2 2025 Calculation
ROE = 100
× (Net income (loss)Q2 2025
+ Net income (loss)Q1 2025
+ Net income (loss)Q4 2024
+ Net income (loss)Q3 2024)
÷ Shareholders’ equity
= 100 × ( + + + )
÷ =
2 Click competitor name to see calculations.
The financial data reveals notable fluctuations and trends across the reported quarterly periods. A series of observations can be drawn pertaining to net income, shareholders' equity, and return on equity (ROE).
- Net Income (Loss)
- Net income displayed considerable variability over the periods. Initially, it showed strong positive results with figures generally above 600 million US dollars. Peaks were observed in certain quarters such as December 2020 with over 770 million US dollars and in the latter part of 2023 with values exceeding 1 billion US dollars. However, a significant loss occurred in June 2024, with net income plunging to approximately -3.6 billion US dollars, indicating a substantial negative event for that quarter. Following this decline, net income rebounded in subsequent quarters, though values oscillated between approximately 600 million and 1 billion US dollars, demonstrating recovery but maintaining volatility.
- Shareholders’ Equity
- Shareholders’ equity showed a generally increasing trend throughout the observed timeframe. Starting from about 6.46 billion US dollars in early 2020, equity grew steadily, reaching above 17.5 billion US dollars by mid-2025. A brief decline was noted in 2024, coinciding with the large net loss, where equity decreased from approximately 18.5 billion to 14.8 billion US dollars. After this dip, equity resumed its upward trajectory. The growth in equity over the years reflects accumulated retained earnings and possibly other capital-augmenting activities.
- Return on Equity (ROE)
- ROE data was incomplete for the earliest periods but available figures demonstrate a generally strong performance through 2020 and 2021, with values mostly exceeding 20%. ROE peaked above 30% in early 2020, before stabilizing to a range approximately between 20% and 27% through 2022 and 2023, evidencing efficient utilization of equity for generating profits. Notably, ROE sharply declined into negative territory during 2024, reaching lows near -6%, correlating with the substantial net loss experienced in that period. By mid-2025, ROE appeared to recover to a positive figure around 21%, suggesting a return to profitability and effective equity use.
In summary, the analyzed data highlights a company with a pattern of robust profitability and growth in equity, interrupted by a significant downturn in 2024. The recovery in subsequent quarters indicates resilience. The substantial fluctuations in net income and ROE during 2024 are critical points warranting further investigation to understand the underlying causes. Overall, while long-term growth trends are positive, attention to managing volatility is advisable.
Return on Assets (ROA)
Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in thousands) | |||||||||||||||||||||||||||||
Net income (loss) | |||||||||||||||||||||||||||||
Total assets | |||||||||||||||||||||||||||||
Profitability Ratio | |||||||||||||||||||||||||||||
ROA1 | |||||||||||||||||||||||||||||
Benchmarks | |||||||||||||||||||||||||||||
ROA, Competitors2 | |||||||||||||||||||||||||||||
AbbVie Inc. | |||||||||||||||||||||||||||||
Amgen Inc. | |||||||||||||||||||||||||||||
Bristol-Myers Squibb Co. | |||||||||||||||||||||||||||||
Danaher Corp. | |||||||||||||||||||||||||||||
Eli Lilly & Co. | |||||||||||||||||||||||||||||
Gilead Sciences Inc. | |||||||||||||||||||||||||||||
Johnson & Johnson | |||||||||||||||||||||||||||||
Merck & Co. Inc. | |||||||||||||||||||||||||||||
Pfizer Inc. | |||||||||||||||||||||||||||||
Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||||||
Thermo Fisher Scientific Inc. |
Based on: 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q2 2025 Calculation
ROA = 100
× (Net income (loss)Q2 2025
+ Net income (loss)Q1 2025
+ Net income (loss)Q4 2024
+ Net income (loss)Q3 2024)
÷ Total assets
= 100 × ( + + + )
÷ =
2 Click competitor name to see calculations.
The financial data reveals several notable trends in net income, total assets, and return on assets (ROA) over the periods analyzed.
- Net Income (Loss)
- The net income figures exhibit variability with a general upward trend from early 2020 through late 2023. Starting at approximately 602.8 million USD in March 2020, net income peaked at over 1 billion USD in September 2023. There is a noticeable dip in the middle of 2021 around June 2021, where net income drops to about 67 million USD, followed by recovery and growth in subsequent quarters. A significant anomaly appears in June 2024, with a steep negative net income of about -3.6 billion USD, which is an outlier compared to other quarters. Following this, net income returns to positive territory, maintaining levels between 646 million and 1.03 billion USD through mid-2025.
- Total Assets
- Total assets show consistent growth from approximately 8.9 billion USD at the beginning of 2020 to over 24 billion USD by mid-2025. This steady increase indicates ongoing asset accumulation and expansion of the company's balance sheet. However, a temporary decline occurs in June 2024, with total assets dropping from about 23.9 billion to around 20.1 billion USD. After this drop, assets recover and continue their upward trend.
- Return on Assets (ROA)
- The ROA metric, available starting from the end of 2020, generally remains strong and positive through 2023, ranging mostly between 15% and 23%. This suggests effective use of assets in generating profits during this period. However, starting in early 2024, ROA declines sharply, turning negative for multiple quarters—most notably in June 2024 with a low of approximately -4.3%. This negative performance coincides with the significant net income loss and asset reduction noted previously. By the end of the period analyzed, ROA recovers to a positive 15.13%, indicating a return to profitability relative to asset levels.
Overall, the data reflect a period of growth and profitability through 2023, disrupted by a substantial financial setback in mid-2024 marked by high losses and asset decline. The company appears to initiate recovery afterward, restoring positive net income and asset growth along with improved ROA.